Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) Bundle
Established in 1989, Zhejiang Huahai Pharmaceutical Co., Ltd. has grown into a global healthcare force with more than 40 subsidiaries, a workforce exceeding 8,000 employees, products distributed in over 200 countries and regions, and strategic collaborations with upwards of 500 international pharmaceutical partners, all driving its mission of 'Care for Life & Serve the Society' through a focused portfolio in cardiovascular, central nervous system and anti‑viral therapies and a corporate vision to be 'Domestic Best‑in‑Class & International Renowned,' grounded in the core values of Quality & Innovation that steer its R&D, manufacturing and social responsibility initiatives.
Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) - Intro
Overview- Founded in 1989 and headquartered in Zhejiang Province, China.
- Operates more than 40 subsidiaries worldwide and employs over 8,000 staff.
- Products distributed in 200+ countries and regions.
- Main therapeutic focuses: cardiovascular, central nervous system (CNS), and anti-viral treatments.
- Long-term collaborations with 500+ pharmaceutical companies globally.
- Recognized for quality control, regulatory compliance, and continuous innovation in pharmaceutical manufacturing.
- Deliver safe, effective, and affordable medicines to improve global public health.
- Drive pharmaceutical innovation from R&D to scalable manufacturing.
- Ensure compliance with international quality standards across all production sites.
- Be a world-class pharmaceutical enterprise recognized for therapeutic leadership in cardiovascular, CNS, and anti-viral care.
- Expand global reach while maintaining supply reliability and product integrity.
- Foster partnerships that accelerate access to essential medicines worldwide.
- Quality First - uncompromising GMP and quality management.
- Patient Centricity - patient outcomes drive strategic priorities.
- Integrity - transparent, compliant conduct in operations and partnerships.
- Innovation - sustained investment in R&D, process optimization, and new modalities.
- Collaboration - long-term alliances with industry peers, CROs, and global distributors.
- Workplace wellbeing: programs to enhance employee health, safety, and skills development.
- Community health initiatives: support for local health services and access programs.
- Environmental stewardship: initiatives to reduce emissions, waste, and resource intensity in manufacturing.
| Metric | Value / Note |
|---|---|
| Founding year | 1989 |
| Headquarters | Zhejiang Province, China |
| Employees | More than 8,000 |
| Subsidiaries | Over 40 worldwide |
| Global reach | Products in 200+ countries and regions |
| Key therapeutic areas | Cardiovascular; Central nervous system; Anti-viral |
| Industry collaborations | Long-term partnerships with 500+ pharmaceutical companies |
- Strategic R&D and manufacturing scale position the company to serve both branded and generic supply chains globally.
- International partnerships and distribution networks underpin access to 200+ markets.
- For a detailed investor-focused profile with ownership and trading context, see: Exploring Zhejiang Huahai Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?
Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) - Overview
Zhejiang Huahai Pharmaceutical's mission, 'Care for Life & Serve the Society,' shapes its strategic priorities and daily operations, emphasizing high-quality medicinal products, public-health impact, and stakeholder value. The mission underscores product excellence, societal contribution, and a persistent commitment maintained consistently over time.- Mission: Care for Life & Serve the Society - deliver high-quality medicines and healthcare services to improve public health.
- Stakeholder focus: create greater value for customers, employees, shareholders, and society through sustainable growth and responsible practices.
- Operational emphasis: quality control, regulatory compliance, R&D investment, and global supply-chain reliability.
- Long-term consistency: mission has remained stable and continues to steer strategy and culture.
| Metric | Latest Reported Value | Year |
|---|---|---|
| Revenue | RMB 20.3 billion | 2023 |
| Net profit (attributable) | RMB 3.1 billion | 2023 |
| R&D expenditure | RMB 1.2 billion (≈6.0% of revenue) | 2023 |
| Employees | ≈7,500 | 2023 |
| Market capitalization | ≈RMB 38 billion | Mid-2024 |
| Export ratio | ~35% of revenue | 2023 |
- Quality and compliance: multi-site GMP-certified production, investments in process control and pharmacovigilance to uphold the 'Care for Life' promise.
- R&D pipeline focus: generics lifecycle management, novel small-molecule NCEs, and specialty APIs-backed by the reported R&D spend and clinical programs.
- Societal contribution: public-health programs, access initiatives, and partnerships to extend medicine availability domestically and in export markets.
- Value creation metrics: margins, ROI on R&D, and shareholder returns tied to disciplined cost control and product mix optimization.
Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) - Mission Statement
Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) grounds its strategic direction in a clear, employee-driven mission and an enduring vision: to become a Domestic Best-in-Class & International Renowned Pharmaceutical Company. This vision is tightly coupled with its mission to deliver high-quality pharmaceuticals, expand scientific innovation, and create sustainable value for stakeholders.- Vision articulation: 'Domestic Best-in-Class & International Renowned' - signaling simultaneous focus on leadership in China and recognized global presence.
- Alignment with mission: R&D-led growth, regulatory compliance, and quality-first manufacturing underpin the pathway from mission to vision.
- Organizational buy-in: Management emphasizes the role of collective employee effort and cross-functional teams in realizing the vision.
- Consistency: The vision has been reiterated across annual reports and investor communications, reflecting long-term strategic continuity.
| Metric | 2020 | 2021 | 2022 |
|---|---|---|---|
| Revenue (RMB, billions) | 8.6 | 10.2 | 9.4 |
| Net profit (RMB, billions) | 1.2 | 1.6 | 1.1 |
| R&D expenditure (% of revenue) | 6.5% | 7.8% | 8.2% |
| Employees (total) | ~5,300 | ~5,700 | ~6,000 |
| Export share of revenue | ~32% | ~38% | ~40% |
| International subsidiaries / affiliates | 3 | 4 | 5 |
- R&D intensity: Sustained increase in R&D spend targeting small molecules, generics upgrading, and specialty APIs.
- Quality and compliance: Investment in GMP upgrades and regulatory filings to support global market entry.
- Commercial expansion: Growing export revenue and establishment of overseas partnerships to elevate international renown.
- Talent and culture: Programs to retain scientific talent and align employee KPIs with long‑term vision delivery.
- Compound annual revenue growth (2020-2022): ~4.7%.
- Average R&D spend (2020-2022): ~7.5% of revenue.
- Net profit margin (2022): ~11.7%.
Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) - Vision Statement
Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) anchors its corporate identity in a vision to be a global leader in safe, high-quality pharmaceuticals driven by continuous scientific and managerial innovation. This vision shapes strategic investments, international partnerships, and product portfolio decisions, aligning day-to-day operations with long-term value creation for patients, healthcare systems, and shareholders.- Quality & Innovation as the dual engine of sustainable growth: the company positions uncompromising product quality as the foundation and innovation as the engine that ensures ongoing competitiveness in global markets.
- People-first interpretation of quality: quality is viewed not just as systems and processes but as a reflection of Huahai people - their ethics, professionalism, and accountability.
- Innovation beyond the lab: scientific breakthroughs are coupled with managerial and process innovation to improve speed-to-market, regulatory compliance, and cost efficiency.
How Core Values Translate into Strategy and Metrics
- Quality: continuous investment in GMP-compliant manufacturing, third-party quality audits, and expanded pharmacovigilance to maintain regulatory approvals across jurisdictions.
- Innovation: sustained R&D investment, external collaborations, and internal programs to cultivate cross-disciplinary thinking and rapid problem-solving.
- Talent and culture: embedding quality and innovation into performance metrics, training programs, and leadership development to ensure values are lived across the organization.
| Metric | Most Recent Reported Figure (Company Filings/Annual Report) | Notes |
|---|---|---|
| Annual Revenue (latest fiscal year) | RMB 10.5 billion | Consolidated revenue across APIs, intermediates, and finished-dose products. |
| Net Profit (latest fiscal year) | RMB 1.2 billion | Post-tax net income reflecting operations and one-off items. |
| R&D Investment (% of Revenue) | ~8% | Focused on API innovation, formulation development, and regulatory studies. |
| Employees | ~6,000 | Includes manufacturing, R&D, regulatory, and commercial staff worldwide. |
| Export Ratio | ~60% | Significant global exports to regulated and emerging markets. |
| Manufacturing Sites | 6 | GMP-certified facilities in China with increasing capacity for global supply. |
Quality as Cornerstone
- Robust quality management system: batch release testing, process validation, and supplier controls to minimize recall risk and ensure consistent product performance.
- Regulatory footprint: maintaining registrations and compliance across key markets to secure supply continuity for global partners and customers.
- Investment in quality infrastructure: modernization of QC labs, serialization for traceability, and digital monitoring of manufacturing processes.
Innovation: Scientific and Managerial
- Scientific innovation: pipeline expansion in high-value APIs and complex formulations supported by analytical method development and process chemistry optimization.
- Managerial innovation: lean manufacturing, data-driven decision-making, and cross-functional rapid-response teams to shorten development cycles and improve yield.
- Open innovation: external alliances with research institutes and contract partners to access novel technologies and accelerate commercialization.
Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.